An implantable device can be defined as a device that is placed into a surgically or naturally formed cavity of the human body if it is intended to remain there for a period of 30 days or more.

The reconstructive joint replacements segment is expected to have the highest growth rate during the forecast period. Joint replacement is highly sought after sub-segment of the orthopedic implants segment in the global implantable medical devices market.

Cardiovascular implants, dental implants, intraocular lens (IOLS), breast implants, and others make up for rest of the market.

Geographically, North America contributes to ~42% of total market. However, Asia Pacific is anticipated to grow at a higher CAGR due to a large population base, and investments by governments towards improving the healthcare infrastructure.

Japan is the second most prominent market globally. Growth drivers for this market are rising awareness, increasing geriatric population, and rise in the number of musculoskeletal, dental, and other chronic degenerative health conditions.

High price of implantable devices and pricing pressures by bulk buyers are expected to restraint the market growth. The market is fairly consolidated with the top five companies including Johnson & Johnson, Zimmer Biomet, Medtronic, Institut Straumann AG and Stryker accounting for more than 50% of the market. Other key players in the market are Abbott Laboratories, Smith & Nephew, Danaher Corporation, Dentsply Sirona and Boston Scientific Corporation

IESS found that between 12 to 18% of hospital bills have undue items and between 25 to 40% of laboratory tests were not necessary. The data also highlighted that between 2002 and 2015 there was misappropriation of BRL5 billion in the public health system. While in the private healthcare, irregularities included excessive and unnecessary treatment or poor quality care, inadequate marketing of medicines and medical devices and tax evasion.

The report concluded that absence of transparent mechanisms in the healthcare system lead to such practices. The Brazilian healthcare system lacks transparency in pricing of inputs, health services and in the payment process for services. This makes it impossible to compare and control costs in the different steps that involve patient care. This is happening mainly because the model used for health care payments (fee-for-service) has loopholes.

The report suggested that to combat such practices in the industry, the payment systems need to be modernized. Hospitals should be rewarded for efficiency and best clinical outcome to the patient. They should be punished for waste and unnecessary exams, readmissions or worsening of clinical conditions caused by faulty care.

• Number of hospitals: 67
• Number of hospital beds per hospital (average): 129
• Operating rooms per hospital (average): 3.3

Penetration of:

• Ventilators: 124%
• Infusion pumps: 1254%
• MRI: 54%
• PET: 37%
• PACS: 66%
• Ultrasound: 64%

Procedure types:

• Ambulatory: 80%
• Hospitalization: 20%

Download the complete report for more information.